Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval

Executive Summary

Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.

You may also be interested in...

2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma

For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.

Trump Victory To Breathe Life Into Korean Biopharmas?

South Korean analysts and pharma firms are generally viewing Donald Trump's win in the US presidential election as positive for the sector, which is stepping up efforts to enter global markets including the US.

Tiny Mabion Races Big Pharma To EU Rituximab Market

Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts